ASC Therapeutics

We are dedicated to discovering, developing and delivering cures for intractable and rare diseases.

We are passionate about helping patients lead more hopeful, healthier and happier lives

ASC Therapeutics is

"HERE TO CURE".

ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT™ and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc.

The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2022 focusing on several blood disorders.

VISION

To provide cures to patients with intractable diseases through innovative technologies and therapeutics that are both groundbreaking and safe.

FOCUS

ASC Therapeutics strives to discover, develop, and deliver gene and cell treatments to cure intractable and emerging diseases.

DNA

Our diverse team has decades of experience in cutting edge stem-cell and gene therapy research. Together we strive to be innovators to provide platforms to revolutionize the way diseases are treated.

Our Pipeline

Discovery

Preclinical

Phase 1/2a

Phase 2b

GVHD

Cell Therapy/phase 2b

Hemophilia A

Gene Therapy

Hemophilia A

Gene Editing

Hemophilia B

Gene Editing

β-Thalassemia

Gene Editing

Undisclosed

Gene editing, Gene/Cell Therapy

Dicscovery

Preclinical

Phase 1/2a

Phase 2b

Hemophilia A

Gene Therapy

Hemophilia A

Gene Editing

Hemophilia B

Gene Editing

β-Thalassemia

Gene Editing

GVHD

Cell Therapy/phase 2B

Undisclosed

Gene editing, Gene/Cell Therapy

Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.

Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline.  Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.

Our Team

Executive Team

Ruhong Jiang, PhD

Co-founder, President and CEO

Oscar Segurado, MD, PhD

Chief Medical Officer

Allan L. Shaw

Chief Financial Officer

Ruhong Jiang, PhD

Co-founder, President and CEO

Oscar Segurado, MD, PhD

Chief Medical Officer

Allan L. Shaw

Chief Financial Officer

Terry Brown Headshot

Gary Potter

Senior VP, Global Operations

Steve Zhang, PhD

VP, Gene & Cell Therapy

Zoya Gluzman-Poltorak, PhD, MBA

VP, Therapeutic Development

Weicheng Wu, PhD, RAC

VP, Global Regulatory Affairs

Terry Brown

Senior Director, Quality

Jeremy Watts​

Director, Corporate Program Management​

Hemophilia Advisory Board

Mark A. Kay, MD, Ph.D

Dennis Farrey Family Professor in Department of Pediatrics, Professor of Genetics, Stanford University

Kimo Stine, MD

Professor of Pediatrics and Medical Director of the Arkansas Center of Bleeding Disorders at Arkansas Children’s Hospital

Annette Von Drygalski, MD, PharmD, RMSK

Professor of Clinical Medicine, Director of the Hemophilia and Thrombosis Treatment Center at UCSD

Gili Kenet, MD

Professor and chair of the hematology Department at the Sackler Medical School, Tel Aviv University

Steven Pipe, MD, PhD

Professor of Pediatrics and Pathology, Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program at the University of Michigan

Mark A. Kay, MD, Ph.D

Dennis Farrey Family Professor in Department of Pediatrics, Professor of Genetics, Stanford University

Kimo Stine, MD

Professor of Pediatrics and Medical Director of the Arkansas Center of Bleeding Disorders at Arkansas Children’s Hospital

Annette Von Drygalski, MD, PharmD, RMSK

Professor of Clinical Medicine, Director of the Hemophilia and Thrombosis Treatment Center at UCSD

Gili Kenet, MD

Professor and chair of the hematology Department at the Sackler Medical School, Tel Aviv University

Steven Pipe, MD, PhD

Professor of Pediatrics and Pathology, Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program at the University of Michigan

Cell Therapy Advisory Board

Olle Ringdén, MD, PhD

Professor of Transplantation Immunology, Karolinska Institute

Behnam Sadeghi, MD, PhD

Head of translational cell therapy Research group, Karolinska Institute

John E. Wagner, MD

Director of the Institute for Cell, Gene and Immunotherapy and Member of the BMT Program, University of Minnesota

Robert Negrin, MD

Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University.

Robert Negrin, MD

Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University.

Olle Ringdén, MD, PhD

Professor of Transplantation Immunology, Karolinska Institute

Behnam Sadeghi, MD, PhD

Head of translational cell therapy Research group, Karolinska Institute

John E. Wagner, MD

Director of the Institute for Cell, Gene and Immunotherapy and Member of the BMT Program, University of Minnesota

Maple Syrup Urine Disease Advisory Board

Guangping Gao, PhD

AAV gene therapy pioneer

Kevin Strauss, MD

PI of Zolgensma gene therapy

Guangping Gao, PhD

Biomedical Research, University of Massachusetts Medical School

Guangping Gao, PhD

AAV gene therapy pioneer

Kevin Strauss, MD

PI of Zolgensma gene therapy

Dan Wang, PhD

Biomedical Research, University of Massachusetts Medical School

Investors

Hermed Capital

Hermed Capital Fund (the “Fund”) is a private equity fund that will invest primarily in healthcare industry around the world.

Fosun International

Fosun International Limited is a technology-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007.

Ping An Group

Ping An of China is devoted to becoming a world-leading personal financial services provider.

Simcere

Simcere Pharmaceutical Group is China's leading R&D-driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China and in the top 10 of the most innovative pharmaceutical companies in China for several consecutive years. Simcere was the first Chinese biological and chemical pharmaceutical company to be listed on the New York Stock Exchange.

Advantech Capital

Launched in January 2016 by Mr. Jianming Yu, Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.

Partners

Stanford University

Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. Stanford is known for its academic achievements, wealth, close proximity to Silicon Valley, and selectivity; it ranks as one of the world's top universities.

Emory University

Emory University, a top-ranked private institution recognized internationally for its outstanding liberal arts colleges, graduate and professional schools, and one of the world's leading healthcare systems, is located on a beautiful campus in Atlanta, Georgia's historic Druid Hills neighborhood.

Shantou University

Shantou University, a key comprehensive university under the provincial Project 211 program in Guangdong, was founded in 1981 with the approval of the State Council. It is the only public university that receives funding from the Li Ka Shing Foundation.

Peking University Shenzhen Hospital

Peking University Shenzhen Hospital, opened in 1999, is a modern general hospital based in Shenzhen with an investment of RMB 4.5 billion. Under the cooperation of Shenzhen municipal government and Peking University, the hospital was absorbed into the management system of Peking University Hospital in the year 2001.

ASC Therapeutics

Company Timeline

2008

Stem cell and gene
editing platforms for
research

2018

IND enabling stage for
two programs

2020

Applied stem cell spinoff in
June 2020 Received two
FDA’s orphan drug

2022

FDA's Fast Track Designation and
EMA's Orphan Drug Designation for ASC618

$19m

$80m

Gene and cell
therapeutic division

2016

ASCT incorporated in
July 2019

2019

IND Clearance for ASC618

2021

$5m

$19m

$44m

$55m

$65m

$80m

2008

Stem cell and gene editing platforms for research, bio-production.

2016

Gene and cell therapeutic division

2018

IND enabling stage for two programs

2019

ASCT incorporated in July 2019

2020

Applied stem cell spinoff in June 2020 received two FDA’s orphan drug designation

2021

IND Clearance for ASC618

2022

FDA's Fast Track Designation and EMA's Orphan Drug Designation for ASC618